Literature DB >> 11836594

Prognostic significance of a combination of thymidylate synthase and dihydropyrimidine dehydrogenase activities in grades 1 and 2 superficial bladder cancer.

Yoichi Mizutani1, Hiromi Wada, Osamu Yoshida, Masakazu Fukushima, Benjamin Bonavida, Akihiro Kawauchi, Tsuneharu Miki.   

Abstract

There is no potent prognostic marker for recurrence in superficial bladder cancer at present. Thymidylate synthase (TS) is a key enzyme for pyrimidine synthesis. Dihydropyrimidine dehydrogenase (DPD) is an important pyrimidine salvage enzyme. We evaluated a combination of TS and DPD activities as a prognostic marker for recurrence in grade 1 and 2 superficial bladder cancer. The levels of TS and DPD activities in non-fixed fresh frozen bladder cancer specimens were determined biochemically by the 5-fluoro-2'-deoxyuridine 5'-monophosphate binding assay and the 5-fluorouracil degradation assay, respectively. Significantly, patients with low TS activity and high DPD activity had a longer post-operative tumor-free interval than those with either high TS activity or low DPD activity in the 2-year follow-up. There were no statistical differences observed in patient's sex and age as well as the histologic stage and grade of bladder cancer between the two groups. In addition, there is no correlation between TS and DPD activities. The present study suggests that a combination of TS and DPD activities may be an independent prognostic indicator for recurrence in grade 1 and 2 superficial bladder cancer, and that either high TS activity or low DPD activity predicts early recurrence.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11836594

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  2 in total

1.  Predictive value of thymidylate synthase for the prognosis and survival of lung adenocarcinoma patients.

Authors:  Yan Huang; Xiuhua Guo; Hongyang Wang; Tienian Zhu
Journal:  Oncol Lett       Date:  2014-11-03       Impact factor: 2.967

2.  Expression level of dihydropyrimidine dehydrogenase is associated with clinical outcome in patients with T1G3 bladder cancer treated with Bacillus Calmette-Guerin.

Authors:  Hiroki Ide; Eiji Kikuchi; Shuji Mikami; Akira Miyajima; Mototsugu Oya
Journal:  BMC Res Notes       Date:  2014-09-13
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.